Chronic obstructive pulmonary disease (COPD) is characterised by chronic airflow limitation and inflammation of the airways and lung parenchyma. COPD is associated with many comorbidities, especially cardiovascular disease (CVD), which share similar risk factors with COPD [1].
The median hpMFAP4 was 11.7 U·mL −1 in first hpMFAP4 quartile (Q1), 19.3 U·mL −1 in the fourth quartile (Q4) and the range was 2.6-69.2 U·mL . hpMFAP4 was significantly lowered by current smoking in COPD patients, with 56% current smokers in Q1 and 27% in Q4, respectively ( p<0.001). Smoker pack-years did not affect hpMFAp4 significantly and hpMFAP4 levels were stratified by current smoking.
hpMFAP4 associated positively and significantly with 6-min walk distance, post-bronchodilator (PD) forced expired volume in 1 s (FEV1) and PD-FEV1 % predicted, but not with decline in FEV1. Likewise, hpMFAP4 associated with the presence of CVD history (32%) and mortality throughout the 3-year study period (total of 30 participants died) (table 1). These significant positive associations were observed in former smokers but not in current smokers after stratification. In hpMFAP4 Q1, 30% of patients had a history of CVD whereas this fraction was increased to 44% in Q4 ( p<0.001). Mortality increased from 1.6% in Q1 to 5.6% in Q4 ( p=0.04). We have shown that elevated hpMFAP4 levels are directly related to the highest lung function measures, the lowest disease grading and emphysema in COPD patients. These relationships were only evident for former smokers and appeared to be disrupted or inverted by current smoking. Although we observed such significant relationships, hpMFAP4 did not appear to be a strong pulmonary marker due to the effect of smoking, and because the variation was not sufficiently strong to predict a fall in lung function or an increase in emphysema development during the 3-year study period. In a previous smaller, yet similar study, we demonstrated that circulating MFAP4 was stable in stable COPD patients but was induced 40-50% 1-6 months after an acute exacerbation. This former study demonstrated significant observations between circulating MFAP4 and various pulmonary outcomes in COPD. However, the previously observed effect sizes were not similar to those currently observed, and circulating MFAP4 was not significantly different between COPD subjects and control subjects [10] . This finding underscores that MFAP4 has no clinical efficacy as marker of lung disease. In line with this notion, circulating MFAP4 did not previously detect any significant changes in idiopathic pulmonary fibrosis, even though a marked significant induction was recognised to occur in the fibrotic lung in vivo [14] and in liver parenchyma as well as in blood in liver fibrosis [7] .
hpMFAP4 was associated with disease history and death in former smokers, and again the relationship appeared to be disrupted by current smoking. However, a similar association to mortality in peripheral artery disease was previously observed [11] and suggests that the variation of circulating MFAP4, which was also observed in the present study is a consequence of cardiovascular disease.
The strong influence of current smoking on circulating levels appear to hamper the use of MFAP4 in diseases without strong induction of circulating levels, such as in liver fibrosis [7] . Nevertheless, circulating MFAP4 appears to be a relevant biomarker to identify COPD patients at risk of death and cardiovascular comorbidity after smoking cessation. Our observations of MFAP4 association with CVD and death in this cohort resembles previous conclusions obtained when testing desmosine variation [12] . As MFAP4 colocalises with elastin in vivo [13] and binds elastin in vitro [2] , we suggest that the observed significant hpMFAP4 variation predominantly reflects elastin degradation, potentially caused by aberrant inflammation in vascular tissues, contributing to worse cardiovascular outcomes and mortality, in line with the previously observed variation for desmosine.
Our study suggests that hpMFAP4 in patients with COPD is a useful marker of cardiovascular risk and mortality. 
